Table 2.

Distribution and overall effect of ENG Thr5Met on liver fibrosis progression in the discovery cohort and the French and Swiss replication cohorts.

	Discovery		French replication		Swiss replication		All Cohorts		OR [95%CI] (a)	P-value(a)
	No fibrosis	Severe fibrosis	No fibrosis	Severe fibrosis	No fibrosis	Severe fibrosis	No fibrosis	Severe fibrosis
	N = 40	N = 48	N = 102	N = 59	N = 148	N = 308	N = 290	N = 415
N carriers(b) (%)	0 (0)	4 (8.3%)	4 (3.9%)	6 (10.2%)	4 (2.7%)	23 (7.5%)	8 (2.8%)	33 (8.0%)	3.04 (1.39–6.69)	0.0024

^(a)Computed by means of the likelihood ratio test in the logistic regression framework.

^(b)All carriers were heterozygous for Thr5Met.